Detailed Study of the Nitric Oxide Synthase Brain - Pipeline Review, H1 2017

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. Nitric oxide synthase 1 or NOS1 is an enzyme encoded by the NOS1 gene. It produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter.

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report covers products from therapy areas Central Nervous System and Oncology which include indications Dementia, Dyskinesia, Brain Injury, Melanoma, Migraine, Musculoskeletal Pain, Neuro Muscular Disorders, Neurodegenerative Diseases, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD) and Visceral Pain.

Complete report available @ Nitric Oxide Synthase Brain - Pipeline Review, H1 2017

The latest report Nitric Oxide Synthase Brain - Pipeline Review, H1 2017, outlays comprehensive information on the Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)
- The report reviews Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)targeted therapeutics and enlists all their major and minor projects 
- The report assesses Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Eli Lilly and Company Neurophyxia BV 

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###